NCIt definition : A humanized, Fc-engineered bispecific monoclonal antibody directed against both the
human negative immunoregulatory checkpoint receptor, programmed cell death protein
1 (PD-1; PCD-1; CD279), and inducible T-cell co-stimulator (ICOS; CD278), with potential
immunomodulating and antineoplastic activities. Upon administration, izuralimab targets
and binds to both PD-1 and ICOS expressed on certain T-cells, including tumor-infiltrating
lymphocytes (TILs). This prevents the activation of PD-1 by its ligands, programmed
cell death-1 ligand 1 (PD-L1) and PD-1 ligand 2 (PD-L2), and stimulates ICOS-mediated
signaling, which promotes the activation of T-cells and enhances T-cell-mediated immune
responses against tumor cells. Combined PD-1 blockade and ICOS stimulation may enhance
T-cell activation and proliferation more than targeting each receptor individually.
The engineered Fc domain increases the stability and half-life of the antibody.;
Semantic type(s)